Antibacterial Nanoparticles Therapeutic (ANT) Study

The Defense Health Agency, through the Army Medical Research Acquisition Activity, issued this special notice regarding the Antibacterial Nanoparticles Therapeutic (ANT) Study. The University of Notre Dame will conduct research to test innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against combat-relevant, multi-drug resistant strains of Pseudomonas aeruginosa. This pathogen causes severe and potentially fatal infections in service members following battlefield injuries. The project utilizes a unique, patented technology held by the University of Notre Dame to develop life-saving therapeutics intended to reduce morbidity and mortality while enhancing operational readiness.

The government anticipates that these collaborative efforts will support future Food and Drug Administration approval of the therapy, contributing to advanced combat medicine and broader biosecurity initiatives. This requirement is classified under NAICS 541713 for Research and Development in Nanotechnology and PSC AN13 for Health R&D Services; Health Care Services; Experimental Development. There is no set-aside assigned to this action.

The primary place of performance is Silver Spring, Maryland. Responses regarding this notice are due by April 28, 2026. Detailed information is provided in the solicitation PANDHA-26-P-0000_036893, and one attachment titled "B01. Notice of Intent to Sole Source PANDHA-26-P-0000 036893.pdf" was published on April 14, 2026. Linda Hinson serves as the point of contact for this requirement.